//Enabling global analysis of protein expression by next generation sequencing

Enabling global analysis of protein expression by next generation sequencing

June 7, 2017

Amgen Innovator Series

Luciano Brocchieri, PhD
Co-Founder, TB-SEQ

TB-SEQ, Inc., promotes implementations and development of the RIBO-seq platform technology, by which protein expression can be monitored and discovered with high coverage and resolution by deep-sequencing the ‘translatome’, i.e., the genome-wide pool of translated mRNAs. Selective translational control of gene expression is emerging as a widespread mechanism for the regulation of functional activities of biological systems. RIBO-seq has enabled discovery of key regulatory components and mechanisms of post-transcriptional control of translation, uncovering new functionalities and targets for intervention.

About Luciano Brocchieri
Luciano Brocchieri, PhD, Co-Founder of TB-SEQ, was formerly a Senior Scientist at Stanford University, Dept. of Mathematics, and a faculty member at the University of Florida, Department of Molecular Genetics and Microbiology. Luciano has a background in theoretical population genetics, bioinformatics, and molecular evolution. He is the author of extensive work on properties and evolution of protein families and nucleic acid sequences and has developed new methods for gene identification and for the analysis of sequencing data. Luciano is also Editor-in-Chief of the Journal of Phylogenetics and Evolutionary Biology. Along with TB-SEQ Co-founder Silvia Tornaletti, a Stanford-educated biochemist and former faculty member at the University of Florida, have previously collaborated on the analysis of translation in the bacterial pathogen Pseudomonas aeruginosa and in aging muscle.

2018-09-23T08:52:06+00:00June 7th, 2017|Events 2017|